REVIEW ARTICLE

Practical application of brief cognitive tests


Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Centro de Salud Pedro Lain Entralgo, Servicio Madrileño de Salud, Alcorcón, Madrid, Spain
Centro Alzheimer Fundación Reina Sofía—Fundación CIBERencia, Madrid, Spain
Centro de Salud Universitario Barrio del Pilar, Universidad Autónoma de Madrid, Madrid, Spain
Facultad de Psicología, Universidad de Barcelona, Barcelona, Spain
Servicio de Neurología, Hospital Universitario de la Princesa, Madrid, Spain
Departamento de Neurología, Hospital Josep Trueta, Girona, Spain
Unidad de Valoración de la Memoria y Demencias, Instituto de Asistencia Sanitaria, Salt, Girona, Spain
Sección de Neurología, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain
Unidad de Demencia, Hospital de la Santísima Trinidad, Salamanca, Spain
Sección de Neurología, Hospital Insular de Canarias, Las Palmas de Gran Canaria, Spain
Departamento de Medicina Interna, Servicio de Medicina Interna, Hospital Reina Sofía, Tudela, Navarra, Spain
Sección de Neurología de la Conducta y Demencias, Servicio de Neurología, Hospital del Mar, Barcelona, Spain
Unidad de Neurología Cognitiva y Conductual, Servicio de Neurología, Hospital Universitario Virgen de las Nieves, Granada, Spain
FIDYAN Neurocenter, Granada, Spain

Received 5 July 2015; accepted 28 July 2015

Abstract

Introduction: Brief cognitive tests (BCT) may help detect cognitive impairment (CI) in the clinical setting. Several BCT have been developed and/or validated in our country, but we lack specific recommendations for use.

Development: Review of studies on the diagnostic accuracy of BCT for CI, using studies conducted in Spain with BCT which take less than 20 minutes. We provide recommendations of use based on expert consensus and established on the basis of BCT characteristics and study results.

Conclusion: The Fototest, the Memory Impairment Screen (MIS) and the Mini-Mental State Examination (MMSE) are the preferred options in primary care; other BCT (Clock Drawing Test [CDT], test of verbal fluency [TVF]) may also be administered in cases of negative results with
persistent suspected CI or concern (stepwise approach). In the specialised care setting, a systematic assessment of the different cognitive domains should be conducted using the Montreal Cognitive Assessment, the MMSE, the Rowland Universal Dementia Assessment, the Addenbrooke's Cognitive Examination, or by means of a stepwise or combined approach involving more simple tests (CDT, TVF, Fototest, MIS, Memory Alteration Test, Eurotest). Associating an informant questionnaire (IQ) with the BCT is superior to the BCT alone for the detection of CI.

The choice of instruments will depend on the patient’s characteristics, the clinician’s experience, and available time. The BCT and IQ must reinforce—but never substitute—clinical judgement, patient–doctor communication, and inter-professional dialogue.

© 2015 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.

PALABRAS CLAVE
Test cognitivos breves;
Deterioro cognitivo;
Detección;
Cribado;
Atención primaria;
Atención especializada

Aplicación práctica de los test cognitivos breves

Resumen
Introducción: Los test cognitivos breves (TCB) pueden ayudar a detectar el deterioro cognitivo (DC) en el ámbito asistencial. Se han desarrollado y/o validado varios TCB en nuestro país, pero no existen recomendaciones específicas para su uso.

Desarrollo: Revisión de estudios sobre el rendimiento diagnóstico en la detección del DC llevados a cabo en España con TCB que requieran menos de 20 min y recomendaciones de uso consensuadas por expertos, sobre la base de las características de los TCB y de los estudios disponibles.

Conclusión: El Fototest, el Memory Impairment Screen (MIS) y el Mini-Mental State Examination (MMSE) son las opciones más recomendables para el primer nivel asistencial, pudiendo añadirse otros test (Test del Reloj [TR] y test de fluidez verbal [TFV]) en caso de resultado negativo y queja o sospecha persistente (aproximación escalonada). En el segundo nivel asistencial es conveniente una evaluación sistemática de las distintas áreas cognitivas, que puede llevarse a cabo con instrumentos como el Montreal Cognitive Assessment, el MMSE, el Rowland Universal Dementia Assessment o el Addenbrooke’s Cognitive Examination, o bien mediante el uso escalonado o combinado de herramientas más simples (TR, TVF, Fototest, MIS, Test de Alteración de la Memoria y Eurotest). El uso asociado de cuestionarios cumplimentados por un informador (CCI) aporta valor añadido a los TCB en la detección del DC.

La elección de los instrumentos vendrá condicionada por las características del paciente, la experiencia del clínico y el tiempo disponible. Los TCB y los CCI deben reforzar —pero nunca suplantar— el juicio clínico, la comunicación con el paciente y el diálogo interprofesional.

© 2015 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Population ageing has increased the prevalence of cognitive impairment (CI) and dementia associated with neurodegenerative, vascular, psychiatric, or other medical conditions, many of which are modifiable. Early diagnosis is vital, as professionals, governments, and groups involved advocate, since there are both preventive and palliative pharmacological and non-pharmacological treatments which can significantly reduce the personal, family, and social burden.

Most of the cases of dementia are preceded by an objectively measured cognitive dysfunction called mild CI (MCI). This syndromic entity, although aetologically heterogeneous, involves a high risk of developing dementia, but it also offers a great opportunity to assess possible preventive interventions. In normal clinical practice, patients who visit our consultation are in different stages of CI, and the line separating MCI and dementia is not clear. Therefore, it seems logical to focus diagnostic efforts towards the identification of the complete CI spectrum, both the earliest variants (MCI) and the more advanced ones (dementia).

A recent population-based study conducted in patients older than 65 in Spain reported a prevalence of MCI of 20%. Despite this high prevalence, many of these cases are still to be diagnosed or properly registered, in contrast to the high frequency of memory loss complaints reported in medical consultations. The reasons for this underdiagnosis could be: lack of access or time during consultations, limited training, confidence or diagnostic certainty of professionals, lack of efficient detection tools, or inappropriate use of these tools.

When MCI is suspected, it is fundamental to first rule out confusional syndrome or acute or subacute (less than 3 months of progression) focal neurological symptoms. These symptoms are markedly different from CI (of chronic
nature), need emergency care (usually in-hospital),\textsuperscript{9} and require assessment with specific tools.\textsuperscript{16} By definition, CI must be detected and diagnosed using tests that assess the patient’s cognitive capacities within the traditional yet irreplaceable framework of the clinical method.\textsuperscript{17} The information provided by a close acquaintance (regarding cognitive capabilities and performance of daily activities) and the results on the mental state examination (MSE)\textsuperscript{18} are especially important for the clinical method (Fig. 1).

Excellent review studies on the diagnostic value of brief cognitive tests (BCT) for detecting dementia have been conducted.\textsuperscript{19–21} However, their usefulness in detecting CI has been much less studied.\textsuperscript{21} The aim of this study is to review the usefulness of BCT and offer recommendations on their rational use in healthcare settings as the first approach to patients with suspected CI or cognitive complaints. We hope to aid in the achievement of more efficient and accurate diagnoses and early therapeutic intervention which could prevent or delay development of dementia, and reduce its high personal, family, and social costs.

Development

Methods

This review article assesses the main characteristics of BCT and offers recommendations for use in clinical practice. In general, any cognitive test which takes less than 20 minutes to be administered is a BCT. In issuing recommendations for use, we considered the 2 main levels in which healthcare systems are organised: first level or primary care (PC) and second level or specialised care (SC). The first level of care normally constitutes patients’ first encounter with the healthcare system. This level provides outpatient care at a healthcare centre or at the patients’ home and also includes prevention and early detection strategies. The second level provides care to patients transferred from the first and second levels through consultations, admitted patient units, home-based care units, and emergency services. Healthcare services also interact with other social and healthcare institutions that provide additional care services or cover specific needs (medium-stay hospitals, day care centres, institutions for the elderly, etc.). Table 1 shows the definition of levels of care, adapted to the goals of this study.

The most accessible and immediate level of care is PC, and professionals at this level have a longitudinal perspective of the patient which is essential for detecting CI, especially when patients have a high education or intellectual level, or there is no informant available. Professionals at the SC level do not usually have previous knowledge of the patient. However, they do have more experience and resources for less common tasks. PC is, therefore, the correct level for detection and early management of CI, while SC is the right level for confirming diagnoses, determining the aetiology, and starting specific treatment.

This article does not address systematic detection of CI in the population, since this process\textsuperscript{3} and its methodology are unclear.\textsuperscript{22} We have not assessed either telephone or internet-based cognitive tests, or self-administered tests or those administered by a caregiver. These may be useful options for patients living in isolated areas, having impaired

![Figure 1](https://example.com/figure1.png)

*Specific elements.

**Table 1** Definition of the levels of care used in this article.

<table>
<thead>
<tr>
<th></th>
<th>First level of care (PC)</th>
<th>Second level of care (SC)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
<td>Area of medical intervention, public or private, which the patient or an informant visits on their own initiative</td>
<td>The patient is referred by another professional, from any speciality or healthcare level, due to suspicion of cognitive impairment</td>
</tr>
<tr>
<td><strong>Professionals involved</strong></td>
<td>General practitioners and nurses</td>
<td>Neurologists, psychologists, geriatric specialists, psychiatrists, internists</td>
</tr>
</tbody>
</table>
Table 2  BCT validation studies for the detection of CI conducted in Spain.

<table>
<thead>
<tr>
<th>BCT</th>
<th>Scope</th>
<th>No. of subjects (CN/MCI/DEM)</th>
<th>COP</th>
<th>S</th>
<th>Spec</th>
<th>AUC</th>
<th>Observations</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>GIT (5 × 5)</td>
<td>SC</td>
<td>192 (62/NS/NS)</td>
<td>19/20</td>
<td>0.89</td>
<td>0.82</td>
<td>0.94</td>
<td>Score range: 0-10</td>
<td>Ferrero-Arias 2001</td>
</tr>
<tr>
<td></td>
<td>SC</td>
<td>153 (66/21/66)</td>
<td>8/9</td>
<td>0.76</td>
<td>0.70</td>
<td>0.88</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clock drawing test</td>
<td>SC</td>
<td>307 (131/112/64)</td>
<td>5/6</td>
<td>0.76</td>
<td>0.78</td>
<td>0.84</td>
<td>Score range: 0-7, consecutive recruitment</td>
<td>Carnero-Pardo 2013</td>
</tr>
<tr>
<td></td>
<td>PC</td>
<td>307 (131/112/64)</td>
<td>1/2</td>
<td>0.60</td>
<td>0.90</td>
<td>0.78</td>
<td>Consecutive recruitment</td>
<td></td>
</tr>
<tr>
<td>Mini-Cog</td>
<td>PC</td>
<td>307 (131/112/64)</td>
<td>19/20</td>
<td>0.89</td>
<td>0.82</td>
<td>0.94</td>
<td>Amnestic-type MCI and dementia due to AD</td>
<td>Carnero-Pardo 2013</td>
</tr>
<tr>
<td>Episodic memory test</td>
<td>SC</td>
<td>378 (225/58/95)</td>
<td>28/29</td>
<td>0.90</td>
<td>0.90</td>
<td>0.95</td>
<td>12% illiterate</td>
<td></td>
</tr>
<tr>
<td>Fototest</td>
<td>PC</td>
<td>589 (361/106/122)</td>
<td>28/29</td>
<td>0.71</td>
<td>0.84</td>
<td>0.95</td>
<td>Multi-centre study</td>
<td></td>
</tr>
<tr>
<td>SC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SC</td>
<td>PC</td>
<td>407 (105/99/203)</td>
<td>28/29</td>
<td>0.83</td>
<td>0.96</td>
<td>0.93</td>
<td>76% with no primary studies</td>
<td>Carnero-Pardo 2013</td>
</tr>
<tr>
<td>MIS</td>
<td>SC</td>
<td>120 (43/19/29)</td>
<td>4/5</td>
<td>0.92</td>
<td>0.81</td>
<td>0.92</td>
<td>Consecutive recruitment, was not applied to 14% of illiterate patients</td>
<td>Pérez-Martinez 2005</td>
</tr>
<tr>
<td></td>
<td>PC</td>
<td>140 (55/37/48)</td>
<td>4/5</td>
<td>0.73</td>
<td>0.87</td>
<td>NS</td>
<td></td>
<td>Carnero-Pardo 2013</td>
</tr>
<tr>
<td>MoT</td>
<td>SC</td>
<td>88 (27/27/34)</td>
<td>36/37</td>
<td>0.93</td>
<td>1.00</td>
<td>0.99</td>
<td>Only amnestic-type MCI included</td>
<td>Rami 2007</td>
</tr>
<tr>
<td></td>
<td>PC</td>
<td>139 (56/36/47)</td>
<td>36/37</td>
<td>0.88</td>
<td>0.68</td>
<td>NS</td>
<td>Consecutive recruitment, 14% illiterate</td>
<td>Carnero-Pardo 2011</td>
</tr>
<tr>
<td>Eurotest</td>
<td>PC</td>
<td>139 (56/36/47)</td>
<td>22/23</td>
<td>0.77</td>
<td>0.93</td>
<td>NS</td>
<td>Consecutive recruitment, 14% illiterate</td>
<td></td>
</tr>
<tr>
<td>MMSE</td>
<td>SC</td>
<td>91 (43/19/29)</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>0.86</td>
<td>MEC version (score range: 0-35)</td>
<td>Rami 2009</td>
</tr>
<tr>
<td></td>
<td>SC</td>
<td>88 (27/27/34)</td>
<td>26/27</td>
<td>0.79</td>
<td>0.84</td>
<td>0.88</td>
<td>Only amnestic-type MCI included</td>
<td>Cacho 2010</td>
</tr>
<tr>
<td></td>
<td>SC</td>
<td>153 (66/21/66)</td>
<td>23/24</td>
<td>0.86</td>
<td>0.84</td>
<td>0.90</td>
<td>Serial subtraction test was not administered and the subject was asked to pick</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SC</td>
<td>194 (63/54/79)</td>
<td>25/26</td>
<td>0.90</td>
<td>0.68</td>
<td>0.90</td>
<td>up the paper with the non-dominant hand, Backward spelling test was not</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PC</td>
<td>360 (146/137/77)</td>
<td>22/23</td>
<td>0.77</td>
<td>0.77</td>
<td>0.84</td>
<td>administered</td>
<td></td>
</tr>
<tr>
<td>MoCA</td>
<td>SC</td>
<td>103 (21/51/31)</td>
<td>19/20</td>
<td>0.76</td>
<td>0.77</td>
<td>0.78</td>
<td></td>
<td>Lozano-Gallego 2009</td>
</tr>
<tr>
<td>RUDAS</td>
<td>SC</td>
<td>115 (50/26/39)</td>
<td>21/22</td>
<td>0.83</td>
<td>0.86</td>
<td>0.90</td>
<td></td>
<td>Ramos-Rios 2009</td>
</tr>
</tbody>
</table>

ACE-III, Addenbrooke's Cognitive Examination (3rd version); MCI, mild cognitive impairment; SC, specialised care; PC, primary care; AUC, area under the ROC curve; CN, cognitively normal; CI, cognitive impairment; DEM, dementia; S, specificity; AD, Alzheimer disease; MEC, Mini-Examen Cognoscitivo; MIS, Memory Impairment Screen; MMSE, Mini-mental State Examination; MoCA, Montreal Cognitive Assessment; NS, non-specified; COP, cut-off point; RUDAS, Rowland Universal Dementia Assessment; S, sensitivity; T@M, memory alteration test; BCT, brief cognitive tests; GIT, general information test; FT, Fototest.

a  BCT influence on diagnosis of cognitive impairment.
b  36/37 if <8 years of schooling, 37/38 if >8 years of schooling.
mobility or other health problems, or with little motivation
to go to a clinic, but evidence is still limited as to their
efficacy.23–25 We briefly describe BCTs which have been val-
dated for detecting CI in Spain, and offer guidelines for their
use. Tests are presented according to their administration
time and only relevant data are mentioned. More informa-
tion on the characteristics, method of administration, and
diagnostic yield of each test can be found in Table 2, as
well as in the validation studies mentioned in the table,25–39
and in a recently published monograph.40 To make compar-
isons between different BCTs easier, we have described only
diagnostic accuracy parameters (sensitivity, specificity, and
the area under the ROC curve [AUC]) corresponding to the
cut-off point that maximises the sum of the sensitivity and
specificity values.

Brief cognitive tests

The animal category fluency trial which lasts just a minute is
the briefest dementia detection test studied.41 It addresses
linguistic and executive skills exclusively, so this type of test
is not recommended as the first option to detect CI. Ver-
bal fluency tests (VFT) offer extremely useful qualitative
and quantitative data within the context of a more com-
prehensive evaluation. The animal naming test and the test
that asks the patient to produce as many words beginning
with "p" in a minute as possible are the most recommended,
since they are complementary and have been well studied
in Spain.42,43 There are some variants, such as the Isaac
Set Test44 and the general information test or the five by
five test,26 which make administration longer and more dif-
ficult without improving diagnostic usefulness. Therefore,
they are not recommended as alternatives.

The clock drawing test (CDT) assesses visuospatial ability
(VA) and executive functions (EF).15 Despite the appeal of
its simplicity and short administration time, the CDT is not
enough in and of itself to detect CI,27 not even in the con-
text of PC15 (Table 2). Nevertheless, the CDT is very sensitive
to damage to the right parietal lobe and is definitely help-
ful as a supplement to other brief tests, especially when no
abnormal performance in memory tests has been detected.
In fact, CDT has been included successfully in several more
comprehensive tests, as we will describe later. Its main dis-
advantage is that minimum drawing skills are necessary to
complete the test, which makes the CDT inappropriate as a
tool for illiterate patients or those with limited graphomotor
skills. There are several proposals for scoring; the simplest
proposals are the most appropriate for detecting CI while
the most complex may be more useful for monitoring studies
and case analysis.40–47

Mini-Cog includes the most frequently affected areas at
CI onset. It includes a 3 word learning test similar to the Fol-
stein Mini-mental State Examination (episodic memory [EM]
and CDT [VA, EF]). Its score range is narrow (0-5: one point
for every recalled word, and 2 additional qualitative assess-
ment points if the clock has all numbers, in the correct order,
and the clock hands point to the requested time) and has lit-
tle sensitivity for detecting CI14 (Table 2) and its monitoring
study. Mini-Cog is most useful in supporting a diagnosis of
dementia, especially in relatively clear cases according to
medical records.

The episodic memory test has been recently created and
validated in a sample of patients with amnestic-type MCI
and Alzheimer disease (AD)35 (Table 2). This is a user-friendly
test which does not require paper or pencil (presumably it is
little influenced by education level). It exclusively assesses
EM through questions regarding the recent past. Its main
disadvantage is that a reliable informant must be present to
corroborate the veracity of the answers.

Fototest comprises a visual-verbal naming task with 6
photographs of objects (language), a verbal fluency task
(language, EF), and an EM task with free and cued recall of
the previously named images. Together with the Folstein
Mini-Mental State Examination (MMSE), Fototest is the most
extensively studied BCT for the detection of CI in Spain. This
is a widely accepted tool that in both PC and SC has shown
a satisfactory usefulness in detecting CI, with a stable cut-
off point (28/29).29,31,32,35 Fototest has also shown a higher
effectiveness ratio than MMSE in PC, with the additional
advantage of having equivalent parallel versions which may
be of help in reducing the practice effect in the case of
repeated administrations (PC, follow-up)48 (Table 2).

The Memory Impairment Screen (MIS) assesses ver-
bal learning (EM) through reading and subsequent free
and cued recall of 4 words. There are several validation
studies conducted in Spain that have shown acceptable
results for detecting CI30,33 (Table 2) and good results for
dementia.30,33,49 especially if due to AD.50 The MIS also
presents a good correlation with hippocampal formation and
entorhinal cortex volumes,51 which supports its potential for
early detection of AD.

The memory alteration test (M@T) includes items related
with EM (free and cued recall, time orientation) and gen-
eral information items (long-term/semantic memory [SM])
to a lesser extent. These characteristics, together with the
wide score range (0-50), make it especially appropriate for
detecting and monitoring the first clinical stages of typical
AD.34,36 (Table 2). The M@T distinguishes between subjective
memory complaints and MCI, and has been validated using
biochemical and neuroimaging markers.52 Although its use-
fulness in PC has been shown,25 limiting this test to SC seems
more realistic and appropriate.

Eurotest is an original proposal for brief cognitive eval-
uation that uses currency coins and consists of 3 parts:
knowledge of current coins (SM), operations with coins (cal-
culation), and recall of the coins used (EM). Eurotest, which
enables to some degree the functional evaluation of the abil-
ity to handle money, has obtained acceptable results in the
detection of CI15 (Table 2) and good results for dementia.30,54
It is an ecologically valid test applicable to illiterate patients
which has additionally been used with different currency
systems, including Chinese.

The MMSE, with its countless adaptations and
translations,55–59 is the most widely used BCT in the
world, both in PC and SC settings. This extensive use,
which enables the comparison and follow-up of subjects
from different origins, has 2 main disadvantages, which
are mainly due to the existence of multiple versions and
the lack of clear instructions for scoring59: a questionable
standard administration procedure and unreliability. Other
limitations of the MMSE are the limited representation of EF,
which diminishes its sensitivity in detecting MCI and fronto-
temporal dementia, and restrictions to its free use due to
its recent copyright licence. The MMSE has been traditionally employed for the detection of dementia; most of the information regarding its usefulness in CI detection comes from validation studies of other tools which included the MMSE as a comparison test. In other studies, the usefulness of the MMSE was, in general, lower than that of the tests to which it was compared (Table 2). In the only specific evaluation study of the MMSE for CI, the best performance was obtained with a lower than usual cut-off point (COP) and in addition, adjusting for age and education did not improve its discriminant ability, unlike in common practice. In any case, MMSE helps to obtain qualitative profiles or features that give confidence to the clinician in the diagnosis and follow up, especially in the case of patients with typical AD. Some examples are the selective alteration of items related to EM (deferred recall, day of the month) in the case of prodromal AD, transformation of pentagons into quadrilaterals in AD with mild dementia, and impaired orientation to month and problems with naming a pencil in the case of moderate AD.

The Montreal Cognitive Assessment (MoCA) has an eclectical and balanced design for the detection of MCI regardless of aetiology. It includes items regarding attention, free recall (list of 5 words), EF (Trail Making Test, similarities), calculation (rating a cube, CDT), orientation, and language. The first validation studies, conducted in Canada, obtained promising results. However, a Spanish study showed a lower effectiveness in the detection of MCI (69% of the subjects were correctly classified vs 90% in the original study) (Table 2). Education level exerts a strong influence on the MoCA, as was shown in validation studies conducted in other countries.

The Rowland Universal Dementia Assessment (RUDAS) was developed in Australia for its administration to multicultural and illiterate populations. It assesses identification of body parts, EM, visuconstructive praxis (drawing a cube), and reasoning. A preliminary study conducted in Spain obtained good results in the detection of CI (26/27) (Table 2).

There are 2 BCTs which have been validated in non-clinical community settings and which therefore do not meet inclusion criteria in this review article. However, we mention them here since they can be useful in PC.

The Abbreviated Mental Test (AMT) by Hodkinson assesses orientation, attention, and memory. The test, which includes 10 items, is easy to administer (except the item requiring the identification of 2 people), and education level is less influential. A COP of 7/8 showed a good performance in the detection of MCI and dementia. The AMT is rarely used in Spain, possibly due to its limited distribution and availability.

The Leganés cognitive test (LCT) was designed to assess the cognitive capacities of an elderly population with a low level of education. It yielded excellent results for the detection of dementia (COP 22/23) and good for CI (COP 26/27). Since most of its items are related to EM, the LCT can be useful for detecting and monitoring typical AD when advanced age, low education level, or other circumstances advise against administering more complex tests.

Other commonly used BCTs in Spain which have been specifically evaluated for use with dementia although not for CI are the following:

The Pfeiffer questionnaire (Short Portable Mental Status Questionnaire [SPMSQ]) is similar to the AMT, although more focused on SM. Mistakes instead of correct answers are scored. The SPMSQ obtained good results in the detection of dementia in PC and SCC (COP 2/3) and excellent results in geriatric settings (COP 4/5).

The 7 Minute Screen (7MS), which requires somewhat more than 7 minutes to administer, presents some characteristics (16 figure learning task, complex score system) that make it difficult to use as a first approach to CI in the healthcare setting. However, being halfway between MSE and formal neuropsychological examination (Fig. 1), it can be a useful tool in the assessment of cognitive areas usually impaired in AD. The 7MS achieves an excellent performance in the detection of dementia (COP 20/21), but an Argentinian study has questioned its usefulness in MCI.

The Addenbrooke’s Cognitive Examination (ACE) was developed from the MMSE, adding frontal/executive and visuospatial elements. Its third version (ACE-III) is currently available and has shown good results with regards to dementia detection, and excellent results with subjects with more than 9 years of schooling (COP 73/74). The ACE can also be useful in distinguishing the main aetiological types of dementia. An abbreviated version has been recently validated (M-ACE) which may have more discriminant ability than the original version.

Limits of the brief cognitive tests: new action and research lines

Without questioning its usefulness and convenience, the diagnostic capability of BCT is far from being completely satisfactory, especially regarding the detection of CI. One solution would be adding more items and areas in order to test more cognitive skills with more detail, but then the test would become less efficient and require more time and specialised personnel. In that case the screening tool and the gold standard would be nearly the same. Another possible solution might consist of using more complex tasks involving diverse cognitive skills, including processing speed (divided attention tasks, figural fluency, etc.). However, a more complex and difficult task is likely to lead to greater influence by non-pathological factors (ageing, stress, etc.), thereby reducing specificity. Using questionnaires on cognitive complaints or metacognition is another option, but this has been demonstrated as less than useful due to the influence of lesion topography, psychiatric comorbidity, and psychological and social factors.

Informant questionnaires are generally simple, easy to administer tools that offer a perspective (longitudinal and that of the informant) supplementary to the one offered by cognitive tests. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) or informant test is the most widely studied questionnaire in Spain. Both the complete version (26 items) and the abbreviated version (17 items) have shown a good performance in the detection of dementia, achieving an AUC of 0.91 in one of the studies. Furthermore, this questionnaire is not influenced by age, sex, mental health, or prior intellectual level. Performance of the IQCODE for the detection of CI was lower (AUC 0.75) in another study, while its incorporation
<table>
<thead>
<tr>
<th>BCT</th>
<th>Time (min)</th>
<th>Assessed areas</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Guidelines for use</th>
<th>Scope</th>
<th>Restrictions on use</th>
<th>Accessibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>VFT</td>
<td>1</td>
<td>L, EF</td>
<td>Very user-friendly</td>
<td>It does not assess EM and requires a stopwatch</td>
<td>It complements other tests</td>
<td>PC, SC</td>
<td>No restrictions or licenses</td>
<td></td>
</tr>
<tr>
<td>Clock drawing test</td>
<td>2</td>
<td>EF, VA</td>
<td>User-friendly, helpful to locate the lesion</td>
<td>It does not assess EM. It includes multiple scoring scales and requires graphomotor skills</td>
<td>It complements other tests</td>
<td>PC, SC</td>
<td>No restrictions or licenses</td>
<td></td>
</tr>
<tr>
<td>Mini-Cog</td>
<td>3</td>
<td>EM, EF, VA</td>
<td>Multi-domain</td>
<td>The score range is narrow. It requires graphomotor skills</td>
<td>Detection of dementia</td>
<td>PC</td>
<td>No restrictions or licenses</td>
<td><a href="http://www.hipocampo.org">www.hipocampo.org</a></td>
</tr>
<tr>
<td>AMT</td>
<td>3</td>
<td>EM, SM, A</td>
<td>Applicable to illiterate patients</td>
<td>Low accessibility and little experience</td>
<td>Detection of dementia</td>
<td>PC</td>
<td>No restrictions or licenses</td>
<td></td>
</tr>
<tr>
<td>SPMSQ</td>
<td>3</td>
<td>EM, SM, A</td>
<td>Applicable to illiterate patients</td>
<td>Prior data should be known. It is not validated for CI</td>
<td>Detection of dementia</td>
<td>PC</td>
<td>No restrictions or licenses</td>
<td><a href="http://www.hipocampo.org">www.hipocampo.org</a></td>
</tr>
<tr>
<td>Fototest</td>
<td>3</td>
<td>EM, EF, L</td>
<td>Applicable to illiterate subjects. It assesses free and cued recall. Parallel versions</td>
<td>It requires a minimum visual acuity</td>
<td>Detection and follow-up of CI and dementia</td>
<td>PC, SC</td>
<td><a href="http://www.fototest.es">www.fototest.es</a>, <a href="http://www.hipocampo.org">www.hipocampo.org</a> (online version)</td>
<td></td>
</tr>
<tr>
<td>MIS</td>
<td>4</td>
<td>EM</td>
<td>Free and cued recall assessment</td>
<td>Reading is needed. It only assesses memory</td>
<td>Detection of CI</td>
<td>PC</td>
<td>Copyright-limited use</td>
<td></td>
</tr>
<tr>
<td>M@T</td>
<td>6</td>
<td>EM, SM</td>
<td>Applicable to illiterate subjects. It assesses free and cued recall, and SM</td>
<td>It only assesses memory</td>
<td>Detection and follow-up of amnestic-type CI and typical AD</td>
<td>SC</td>
<td>Clinical use permitted under copyright</td>
<td><a href="http://www.hipocampo.org">www.hipocampo.org</a></td>
</tr>
<tr>
<td>Eurotest</td>
<td>8</td>
<td>EF, EM, SM, NS</td>
<td>Applicable to illiterate patients, functional assessment</td>
<td>It requires a minimum visual acuity and having coins at hand</td>
<td>Detection and follow-up of CI and dementia</td>
<td>PC, SC</td>
<td><a href="http://www.eurotest.es">www.eurotest.es</a></td>
<td></td>
</tr>
<tr>
<td>MMSE</td>
<td>10</td>
<td>EM, SM, EF, L, A, VA</td>
<td>Universal use, qualitative features</td>
<td>Multiple versions, influence of educational factors</td>
<td>Detection and follow-up of CI and dementia</td>
<td>SC, PC</td>
<td>Copyright-limited use</td>
<td><a href="http://web.teaediciones.com/Inicio.aspx">http://web.teaediciones.com/Inicio.aspx</a> (MEC version)</td>
</tr>
</tbody>
</table>
Table 3 (Continued)

<table>
<thead>
<tr>
<th>BCT</th>
<th>Time (min)</th>
<th>Assessed areas</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Guidelines for use</th>
<th>Scope</th>
<th>Restrictions on use</th>
<th>Accessibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCT</td>
<td>11</td>
<td>EM, L, A, SM</td>
<td>Applicable to the elderly and illiterate subjects Easy administration, and balanced structure</td>
<td>It does not assess EF or VA. Limited distribution in Spain</td>
<td>Detection and follow-up of CI and dementia</td>
<td>PC</td>
<td>No restrictions or licenses</td>
<td></td>
</tr>
<tr>
<td>MoCA</td>
<td>12</td>
<td>EM, SM, EF, L, A, VA</td>
<td>Standardised scoring with a wide range</td>
<td>Little experience in Spain</td>
<td>Detection and follow-up of CI and dementia</td>
<td>SC</td>
<td>Clinical use permitted under copyright</td>
<td><a href="http://www.mocatest.org">www.mocatest.org</a></td>
</tr>
<tr>
<td>7MT</td>
<td>13</td>
<td>EM, EF, L, VA</td>
<td>Scrupulous scoring. It requires a wide range of material (pictures, stopwatch, pencil)</td>
<td></td>
<td>Detection and follow-up of CI and dementia</td>
<td>SC</td>
<td>Copyright-limited use</td>
<td></td>
</tr>
<tr>
<td>RUDAS</td>
<td>13</td>
<td>EM, EF, L, VA</td>
<td>Applicable to illiterate subjects, balanced structure</td>
<td>Little experience in Spain</td>
<td>Detection and follow-up of CI and dementia</td>
<td>SC</td>
<td>Clinical use permitted under copyright</td>
<td><a href="http://www.health.qld.gov.au/tpch/html/rudas.asp">http://www.health.qld.gov.au/tpch/html/rudas.asp</a> (in English)</td>
</tr>
</tbody>
</table>

A, attention; ACE-III, Addenbrooke’s Cognitive Examination (3rd version); SC, specialised care; AMT, Abbreviated Mental Test; PC, primary care; VA, visuospatial area; NS, numerical skills; CI, cognitive impairment; FTLD, frontotemporal lobar degeneration; AD, Alzheimer disease; EF, frontal/executive functions; L, language; EM, episodic memory; MEC, Mini-Cog; min, minutes; MIS, Memory Impairment Screen; MMSE, Mini-mental State Examination; MoCA, Montreal Cognitive Assessment; SM, remote/semantic memory; LCT, Leganés cognitive test; RUDAS, Rowland Universal Dementia Assessment; SPMSQ, Short Portable Mental Status Questionnaire; M@T, Memory alteration test; VFT, verbal fluency test (animals, words beginning with ‘p’); 7MT, 7 Minute Screen.
added predictive value to the MMSE (AUC 0.86 vs 0.82 with MMSE only). The Functional Activities Questionnaire (FAQ) comprises 11 items and has also obtained good results in the detection of dementia (AUC 0.91), although results are poorer for detecting CI (AUC 0.77). The FAQ, like the IQCODE, improved the performance of the MMSE for detecting dementia (AUC 0.95 vs 0.91 with MMSE only). The Ascertain Dementia-8 (AD 8) is a very brief proposal, designed for PC. It includes 8 yes or no questions and presents a good performance for diagnosing CI (AUC 0.90). Furthermore, its use associated with a BCT (Fototest) adds predictive value (AUC of Fototest 0.93 vs AUC of Fototest plus AD 8 0.96).  

Physical examination (motor alterations, frontal signs, etc.) or biological sample analysis (blood, saliva, etc.) could provide other complementary markers for the detection of CI. But these lines of research, though interesting for aetiological diagnosis, have not yet provided evidence of practical usefulness.  

Conclusions  
A first approach to the patient with complaint or suspicion of CI should at minimum include the examination of the more frequently impaired areas (EM and EF). In PC we recommend using some BCT as that could offer objective support to the clinical suspicion and facilitate an efficient referral to SC to obtain an accurate diagnosis. Fototest and MIS have been well studied and are the most recommended options for PC. Other tests (CDT, VFT) can be added, especially in the case of negative results and persistent complaints or suspicions (stepped-care approach). Eurotest and MMSE are also valid alternatives in PC, depending on the circumstances (Eurotest for illiterate patients and MMSE if more time is available) (Table 3). The patient’s performance in his or her day-to-day social environment should be clearly defined both in PC and SC (money handling, medication, etc.). If impairment is observed, suspicion of dementia and not of MCI should be considered.  

A systematic review of the main cognitive areas (attention, language, EM, EF, VA) must be conducted in SC, so a formal neuropsychological examination would be the ideal test (Fig. 1). For this reason, the most recommended tools for this level of care are, theoretically, those permitting evaluation of the highest number of cognitive domains, such as MoCA, MMSE, RUDAS, or ACE-III. These tests should be selected according to patient characteristics (MoCA if the patient is close to normality, MMSE if advanced CI is suspected, RUDAS if the patient is illiterate, ACE-III if in doubt between AD and frontotemporal lobar degeneration), the clinician’s experience, and the available time (ACE-III administration requires more than 15 minutes). Maybe due to the lack of specific studies (ACE-III), modest or negative results available (MMSE, MoCA) or the presence of other disadvantages (MMSE is not free) it is still to be determined whether the use of these tools is more efficient than the use of other brief and simple cognitive tests. This determination should consider that tests can be administered separately (MIS, MoT, and Fototest), combined (VFT, CDT, and MMSE) or in a stepped-care approach (Fototest and Eurotest), particularly in situations with little time available.  

Possible actions to avoid false negatives are varied and efficacious, and implementable in developed countries with enough healthcare and social resources. These include promoting a healthy lifestyle, controlling vascular risk factors, advising, researching, etc. These measures are not risky or costly, and all of them can be addressed or monitored by PC. Using cut-off points other than those recommended is acceptable in order to increase sensitivity and facilitate early detection, especially in cases of persistent complaint or suspicion or in subjects with a prior high intellectual level. Cut-off points serve as a guide and support, but never as confirmation of the diagnosis of CI, which is obtained by clinically assessing all the information available (Fig. 1).  

To diagnose dementia, informant questionnaires perform the same or even better than BCT. This is most likely because a large number of older people in Spain have a low level of schooling, resulting in lower specificity of cognitive tests. However, an MSE should be performed whenever possible, since the target is CI (MCI or dementia) and the informant’s perceptions might not be valid, or might be distorted by primarily non-cognitive aspects (physical health, sensory deficit, etc.), or even self-interest. Informant questionnaires provide added value to BCT, and this synergy should be further investigated. Rigorous, non-stop and imaginative research here in Spain has led to the designing of varied and complementary BCT, which are useful to increase clinicians’ confidence and accuracy in their first approach to the patient with complaint or suspicion of CI. The recommended BCT as well as their cut-off points and instructions, must be accessible in the electronic medical histories in PC and SC when possible in order to facilitate use and make it more cost-effective. BCT potential should be further explored, especially regarding aetiological diagnosis (for example, Eurotest may help detect CI caused by anything other than typical AD) and its usefulness in progression monitoring. Tests and questionnaires should reinforce but never replace medical opinion, fluid communication with patients and their acquaintances, coordination between the different healthcare levels, and dialogue between professionals in healthcare settings.  

Conflicts of interest  
C. Carnero-Pardo is the creator of Fototest and Eurotest. The remaining authors have no conflicts of interest to declare.  

References  


